MPC-0767 is an orally active prodrug of Hsp90 inhibitor. MPC-0767 undergoes rapid biotransformation to the parent Hsp90 inhibitor MPC-3100 via enzyme-mediated luminal cleavage. MPC-0767 is applicable to the research of refractory and recurrent cancers.
Products | Products > Disease Areas > Cancer | Products > Signaling Pathways > Others | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Drug Intermediate
感谢您来到爆牛贸易,请为我们留言或者使用以下方式联系我们,我们将尽快给您回复,并为您提供最真诚的服务,谢谢。